Healthcare Industry News: HSMN NewsFeed
News Release - March 25, 2021
Smith & Nephew adds Movendo Technology's patient rehabilitation solution to Real Intelligence digital ecosystemLONDON, March 25, 2021 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces a marketing collaboration with Movendo Technology (Genoa, Italy) that will add personalised robotic patient rehabilitation capability to Smith & Nephew's Real Intelligence enabling technology solutions, creating a fully digitised patient pathway from the pre-op stage to post-rehab phase. The collaboration has launched in Europe and will expand to other regions in the near future.
Movendo Technology's multifunctional rehabilitation device, HUNOVA, is able to analyse 130 different biomechanics parameters of the lower limb before and after surgery, generating a bespoke functional evaluation knee index. This provides a personalised patient recovery programme to support the return of strength and function of the joint's articulation. The index can also be extended to the hip and ankle.
Smith & Nephew's Real Intelligence ecosystem addresses clinical challenges through the continuum of care including patient engagement, pre-operative planning, digital and robotic surgery, post-operative assessment, and outcomes measurement. Smith & Nephew's next generation robotics-assisted platform, the CORI™ Surgical System, is scheduled to launch in Europe during the first half of 2021 after a successful introduction in the US last year.
"We are thrilled that this collaboration will start in Europe," said Peter Coenen, President EMEA, Smith & Nephew. "By combining our innovations in robotics-assisted surgical systems with HUNOVA Robotic technology, we bring together personalised implant placement and soft tissue balancing with a rehabilitation treatment to deliver greater benefits to patients, accelerate recovery and improve function."
"We are extremely proud and excited about this new partnership that will make robotics-assisted surgery and rehabilitation an integrated, more effective and engaging process," said Simone Ungaro, CEO of Movendo. "I am looking forward to bringing this innovative concept world-wide in collaboration with Smith & Nephew."
The collaboration further emphasises Smith & Nephew's commitment to data driven enabling technologies that allow our customers to provide the highest level of care to their patients. For more information about Real Intelligence, please visit www.real-intelligence.com.
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith & Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms 'Group' and 'Smith & Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith & Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Movendo Technology, part of the biopharmaceutical group Dompé Holdings, was established in 2016. Headquartered in Genoa, Italy with subsidiaries in Munich, Germany, and Boston, USA, Movendo develops and commercialises robotic and digital rehabilitation solutions for objective, functional assessments, and effective treatments. hunova©, the company's flagship product and one of the most versatile robotic assistive device available, improves orthopaedic rehabilitation, the management of neurological and chronic conditions, active aging and athletic performance. Proprietary software algorithms and novel IT solutions provide for predictive and personalised therapy, telerehabilitation as well as for data-driven population health management tools.
For more information about Movendo Technology, please visit www.movendo.technology
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew to expand Real Intelligence digital ecosystem and CORI(TM) Surgical System with total hip arthroplasty
Smith & Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS
New data underscores material benefits of Smith & Nephew's OXINIUM(TM) DH Technology and OR3O(TM) Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners